Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.50 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.50 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.50 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.50 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827764 | 0.85 | NPC1 (0.63) | NPC1TSHRRAB9AMAOBLMNA | |
| SCHEMBL6584443 | 0.82 | CYP1A1 (0.67) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL29217040 | 0.81 | SLC6A4 (0.54) | TSHRCYP2A6PTGDR2ALDH1A1MAPK1 | |
| SCHEMBL5961843 | 0.80 | CYP3A4 (0.53) | NPC1TSHRRAB9ACYP1A1CYP1A2 | |
| SCHEMBL2659108 | 0.80 | MKNK1 (0.62) | NPC1RAB9ACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL24049723 | 0.79 | PGR (0.56) | NPC1RAB9ACYP1A1CYP1A2CYP2E1 | |
| SCHEMBL5632975 | 0.78 | CYP1A1 (0.79) | NPC1RAB9ACYP1A1CYP1A2CYP2E1 | |
| SCHEMBL8502642 | 0.78 | PGR (0.49) | NPC1TSHRRAB9ACYP1A1CYP1A2 | |
| SCHEMBL20550345 | 0.78 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL11962286 | 0.78 | ACHE (0.54) | NPC1RAB9ACYP1A1CYP1A2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-115960032-A | Aryloxy propanol amine beta-adrenaline receptor ligand with beta-arrestin biased agonistic activity and application thereof | 复旦大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-102227436-A | Macrocyclic compounds as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2011-10-26 | — | — | CN | disclosed |
| CN-102066337-A | 5-hydroxypyrimidine-4-carboxamide compounds | DAIICHI SANKYO CO LTD | 2011-05-18 | — | — | CN | disclosed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| CN-1281433-A | Hydroxamic acid derivatives as matrix metalloproteinase (MMP) inhibitors | PFIZER LTD (US) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | NPC1 4280/4885TSHR 2119/4885RAB9A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.